IL86009A - Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases - Google Patents

Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases

Info

Publication number
IL86009A
IL86009A IL86009A IL8600988A IL86009A IL 86009 A IL86009 A IL 86009A IL 86009 A IL86009 A IL 86009A IL 8600988 A IL8600988 A IL 8600988A IL 86009 A IL86009 A IL 86009A
Authority
IL
Israel
Prior art keywords
liposomes
cells
nucleosides
phosphorylated
encapsulated
Prior art date
Application number
IL86009A
Other languages
English (en)
Other versions
IL86009A0 (en
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of IL86009A0 publication Critical patent/IL86009A0/xx
Publication of IL86009A publication Critical patent/IL86009A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
IL86009A 1987-04-10 1988-04-07 Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases IL86009A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3717887A 1987-04-10 1987-04-10
US17778888A 1988-04-05 1988-04-05

Publications (2)

Publication Number Publication Date
IL86009A0 IL86009A0 (en) 1988-09-30
IL86009A true IL86009A (en) 1991-09-16

Family

ID=26713879

Family Applications (1)

Application Number Title Priority Date Filing Date
IL86009A IL86009A (en) 1987-04-10 1988-04-07 Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases

Country Status (8)

Country Link
EP (1) EP0286418B1 (de)
JP (1) JPH02501576A (de)
AT (1) ATE77945T1 (de)
AU (1) AU601848B2 (de)
CA (1) CA1315684C (de)
DE (1) DE3872563T2 (de)
IL (1) IL86009A (de)
WO (1) WO1988007854A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
WO1989002733A1 (en) * 1987-09-22 1989-04-06 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
US5817638A (en) * 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
US5051361A (en) * 1988-10-19 1991-09-24 Sigma Chemical Company AZT immunoassays, derivatives, conjugates and antibodies
FR2640508B1 (fr) * 1988-12-19 1994-07-01 Dietlin Francois Nouvelles compositions et nouveaux produits pharmaceutiques assurant la regeneration de leucocytes et leur emploi pour le traitement du syndrome immuno-deficitaire
EP0464135B1 (de) * 1989-03-13 1996-06-26 MATSUMURA, Kenneth Naoyuki Zusammensetzung zur herabsetzung der nebenwirkungen eines arzneimittels
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
PH30703A (en) * 1990-06-21 1997-09-16 Patrick T Prendergast Administering particular compounds against variousparasites, mycoplasmas, other indications and otheer indications and other infections.
US5137876A (en) * 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
JPH10506396A (ja) * 1994-10-03 1998-06-23 ジェ． ベルジュロン，ミシェル Ａｉｄｓ及びいくつかの他のウィルス性疾患を治療するための方法及び製剤
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
CA2270600A1 (en) * 1999-05-03 2000-11-03 Infectio Recherche Inc. Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
AU2003268087A1 (en) * 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4604382A (en) * 1983-01-17 1986-08-05 Research Corporation 3'-amino-2',3'-dideoxycytidine and the pharmacologically acceptable salts thereof
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4622392A (en) * 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
PT82199B (pt) * 1985-03-16 1990-11-07 Wellcome Found Processo para a preparacao de nucleosidos antivirais e de composicoes farmaceuticas que os contem
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
WO1987001283A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxycytidine
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine

Also Published As

Publication number Publication date
IL86009A0 (en) 1988-09-30
AU1701788A (en) 1988-11-04
DE3872563T2 (de) 1992-12-03
EP0286418B1 (de) 1992-07-08
WO1988007854A1 (en) 1988-10-20
JPH02501576A (ja) 1990-05-31
AU601848B2 (en) 1990-09-20
CA1315684C (en) 1993-04-06
DE3872563D1 (de) 1992-08-13
EP0286418A1 (de) 1988-10-12
ATE77945T1 (de) 1992-07-15

Similar Documents

Publication Publication Date Title
IL86009A (en) Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases
AU2452288A (en) Nucleoside derivatives useful in treating retroviral infections
GB9020586D0 (en) Recombinant retroviruses
AU1189688A (en) Utilization of morphine antagonists in the preparation of drugs having an immunomodulator and antiviral effect, particularly for treating acquired immunodeficiency states
NL960024I1 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus gesmette patiënten.
ATE100098T1 (de) Nukleoside, ihre herstellung und pharmazeutische zusammenstellungen.
KR890001580A (ko) B형 간염 바이러스에 의해 유발되는 염증 질환을 치료하는 이중가닥 rna를 함유하는 약물
ATE78696T1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
ES2081491T3 (es) Nuevo polipeptido y farmaco anti-vih preparado a partir de este polipeptido.
DK462688A (da) Anvendelse af nukleosider til fremstilling af laegemiddel til behandling af sygdomme foraarsaget af retrovirus eller hepatitis b virus
WO1990013281A3 (en) Method of suppressing hiv infection
DK0410749T3 (da) Anthocyanidiner til behandling af ophthalmiske sygdomme
ATE58478T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
MC1930A1 (fr) Produit antiviral
KR910018393A (ko) 항바이러스제로서의 비대칭 2-(포스포노메톡시)프로필 구아닌
ATE222107T1 (de) Verwendung einer kombination von beta-sitosterol und beta-sitosterol-glukosid zur herstellung eines medikamentes zur behandlung von hiv- infektion
FI881123A0 (fi) Inaktivering av human immunodeficiency virus (hiv) medelst fenol i proteinhaltiga loesningar.
DK15088D0 (da) Antibakterielt lyofiliseret praeparat
BR9303733A (pt) Uso,de um composto,substancia ou composicao,na preparacao de uma substancia ou composicao para tratar uma infeccao viral,composto,substancia ou composicao,respectivos usos para,tratamento de uma infeccao viral,como remedio ou medicamento,como agente terapeutico ativo no tratamento de uma infeccao viral;remedio ou medicamento,processo de preparar um composto e processo de tratar uma infeccao viral num ser humano ou animal
MX9706942A (es) Compuestos quimicos.
ATE64855T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
TH3782EX (th) นิวคลีโอไซด์ที่ต่อต้านไวรัส
DE3886526D1 (de) Mittel zur verhinderung der progredienz der erkrankung nach hiv-virusinfektionen.
WO1988008707A3 (en) Rubradirin derivatives for treatment of hiv infection
BR0016844A (pt) Tratamento de infecção de vìrus de imunodeficiência humana resistente a drogas

Legal Events

Date Code Title Description
RH Patent void